Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on June 2, 2022. The record date for the meeting was April 11, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 122,893,661 shares outstanding, 86,890,757 shares (70.70%) were represented at the meeting. The following proposals were approved:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2025 annual meeting:
- Vicki Sato, Ph.D.: 65,468,617 For; 15,480,637 Withheld.
- Erik Harris: 80,619,488 For; 329,766 Withheld.
- Peter Klein: 67,316,812 For; 13,632,442 Withheld.
- Proposal 2 (Ratification of Auditors): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- For: 86,837,219
- Against: 16,399
- Abstain: 37,139
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation.
- For: 75,783,360
- Against: 4,516,536
- Abstain: 649,358
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Vicki Sato, Erik Harris, Peter Klein) through the 2025 annual meeting.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2022.
- Note the significant number of "Withheld" votes for directors Vicki Sato and Peter Klein compared to Erik Harris.
- Review the full Proxy Statement for details on the executive compensation package approved in Proposal 3.